BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-793@pharmaconomics
DTSTAMP:20260707T015600Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:IRD Phase 2 — Phentolamine Ophthalmic Solution 0.75%
DESCRIPTION:Phase 2 trial results for Phentolamine Ophthalmic Solution 0.75% in presbyopia are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1228627/000114036126000615/ef20062523_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/793
URL:https://pharmaconomics.com/e/793
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IRD catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR